


# Synovial sarcoma

Gretchen S. Folk, DDS, MS; Lester D.R. Thompson, MD, FASCP



*Figure 1. This monophasic SS is made up of densely packed and relatively uniform spindle cells. The cells have very little cytoplasm, and their borders are indistinct. Special studies are required to confirm the diagnosis.*

Synovial sarcoma (SS) is a unique tumor that usually involves the large joints. Approximately 10% of these tumors develop in the neck, oropharynx, hypopharynx, and larynx. Despite the name, these tumors neither originate from synovium nor express synovial differentiation. SS typically presents in young adults (median age: 25 yr). The male-to-female ratio is 3:1. Symptoms are site-specific but tend to be nonspecific. SS typically appears as a solitary, painless mass, occasionally accompanied by dyspnea or hoarseness. The diameter of the lesion ranges from 1 to 12 cm. The cut surface is yellow, firm, whorled, gritty, and friable; cyst formation with hemorrhage or mucoid material is often seen.

Histopathologically, SS is either monophasic (epithelial or spindle cells) or biphasic (epithelial and spindle cells).

The most common pattern is the monophasic spindle cell type, which is characterized by short, streaming fascicles of relatively uniform spindle cells with spindled nuclei and indistinct cell borders (figure 1). In biphasic tumors, the epithelial cells are arranged in solid nests, pseudoglands, or papillary structures (figure 2). Their shapes vary from cuboidal to tall columnar. Mitotic activity is easily identified, but it is not increased. Approximately one-third of all synovial sarcomas exhibit focal calcification. Poorly differentiated tumors are characterized by necrosis and increased mitotic figures. Either epithelial or mesenchymal mucin may be identified in each component of a biphasic tumor. Immunohistochemistry is necessary to confirm a diagnosis of SS. Both spindle and epithelial cells express low- and high-molecular-weight cytokeratins and epi-




Figure 2. This biphasic SS exhibits areas of gland formation and papillary structures that are traversed by streaming fascicles of smaller, darker spindle cells.

thelial membrane antigen, but only spindle cells express vimentin and bcl-2.

SS has a unique balanced and reciprocal translocation: t(X;18)(p11.2;q11.2). This finding is not seen in other neo-

plasms. The histologic differential diagnosis is predicated on whether the tumor is biphasic or monophasic; it includes adenocarcinoma, spindle cell carcinoma, fibrosarcoma, malignant peripheral nerve sheath tumor, glomangiopericytoma (hemangiopericytoma), leiomyosarcoma, malignant melanoma, epithelioid sarcoma, and angiosarcoma.

Recurrence rates as high as 25% have been reported, usually within 2 years. Another 25% of cases involve metastasis, usually to the lung, bone, or lymph nodes. The 5-year survival rate is approximately 66%. A more favorable clinical outcome is suggested by a young age at diagnosis, small tumor size (<5 cm), extensive calcification, and complete surgical removal. Therefore, meticulous attention to surgical margins and multimodality therapy (radiation and chemotherapy) will help achieve the best overall outcome.

**Suggested reading**

Dei Tos AP, Dal Cin P, Sciort R, et al. Synovial sarcoma of the larynx and hypopharynx. *Ann Otol Rhinol Laryngol* 1998;107:1080-5.  
 Fisher C. Synovial sarcoma. *Ann Diagn Pathol* 1998;2:401-21.  
 Thompson LDR, Fanburg-Smith JC. Malignant soft tissue tumours. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. *Pathology and Genetics of Head and Neck Tumours*. Kleihues P, Sobin LH, series eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2005:147-9.

**Recommended by over 1,000 ENTs**

**MICHAEL SEIDMAN, MD, FACS**  
 authority on tinnitus and conditions of the inner ear states:

**"IT HAS BEEN MY EXPERIENCE**  
 in treating tinnitus with Arches Tinnitus Relief Formula that 10% enjoy a complete reduction of symptoms, 10% experience no change, and 80% receive some degree of relief from their symptoms, varying by individual. I recommend Arches Tinnitus Relief Formula to many of my patients\* and advise them to take two capsules in the morning and again in the evening and continue this dosage for 100 days before determining the degree of relief Arches Tinnitus Relief Formula will provide."

Dr. Seidman is the Medical Director of Arches and has a small financial interest in the company.



**ARCHES TINNITUS RELIEF FORMULA®**

**CLINICAL STUDIES HAVE SHOWN BOTH GINKGO BILOBA EXTRACT AND CHELATED ZINC EFFECTIVE IN REDUCING TINNITUS.**

- » Hostein N. Ginkgo special extract EGb 761 in tinnitus therapy. A survey of results of completed clinical trials. *Fortschr Med Orig.* 11;118(4):157-64, 2001 Jan. Review.
- » Meyer B. Multicenter randomized double-blind drug vs. placebo study of the treatment of tinnitus with Ginkgo biloba extract. *Presse Med.* 15(31):1562-4, 1986 Sep 25.
- » Morgenstern C, Biermann E. The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. *Int J Clin Pharmacol Ther.* 40(5):188-97, 2002 May.
- » Arda HN, et al. The role of zinc in the treatment of tinnitus. *Otol Neurotol.* 24(1):66-9, 2003 Jan.



**TINNITUS RELIEF IS UNDER THE ARCH**  
**CALL FOR A FREE PHYSICIAN'S BOOKLET PLUS CD**  
**WITH 35 CLINICAL STUDIES, C OF A, & MORE...**

**TOLL FREE 800-350-9631**  
 email: [admin@archesnps.com](mailto:admin@archesnps.com) [www.tinnitusformula.com](http://www.tinnitusformula.com)



**Tinnitus Formulas**

\*Certain people should exercise caution before taking Ginkgo biloba extract. Those taking prescription anticoagulants should consult their physician before use. Discontinue use two weeks prior to any surgical procedure.



Circle 107 on Reader Service Card